ArQule Current Ratio 2006-2019 | ARQL

ArQule current ratio from 2006 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
ArQule Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-03-31 $0.10B $0.02B 6.45
2018-12-31 $0.11B $0.02B 7.28
2018-09-30 $0.11B $0.01B 9.60
2018-06-30 $0.05B $0.01B 5.99
2018-03-31 $0.05B $0.01B 5.42
2017-12-31 $0.05B $0.01B 4.98
2017-09-30 $0.03B $0.01B 3.45
2017-06-30 $0.03B $0.01B 4.33
2017-03-31 $0.04B $0.01B 5.33
2016-12-31 $0.03B $0.01B 3.67
2016-09-30 $0.04B $0.01B 4.51
2016-06-30 $0.04B $0.01B 5.10
2016-03-31 $0.05B $0.01B 5.48
2015-12-31 $0.04B $0.01B 3.65
2015-09-30 $0.04B $0.01B 3.36
2015-06-30 $0.05B $0.02B 3.06
2015-03-31 $0.06B $0.02B 3.30
2014-12-31 $0.06B $0.02B 3.34
2014-09-30 $0.06B $0.02B 3.12
2014-06-30 $0.07B $0.02B 3.06
2014-03-31 $0.07B $0.02B 3.44
2013-12-31 $0.08B $0.02B 3.48
2013-09-30 $0.08B $0.02B 3.38
2013-06-30 $0.08B $0.03B 3.31
2013-03-31 $0.09B $0.02B 3.68
2012-12-31 $0.08B $0.03B 2.99
2012-09-30 $0.08B $0.04B 2.11
2012-06-30 $0.08B $0.04B 1.81
2012-03-31 $0.07B $0.05B 1.51
2011-12-31 $0.07B $0.05B 1.48
2011-09-30 $0.11B $0.06B 1.73
2011-06-30 $0.09B $0.06B 1.46
2011-03-31 $0.11B $0.05B 2.09
2010-12-31 $0.08B $0.05B 1.74
2010-09-30 $0.09B $0.04B 2.08
2010-06-30 $0.11B $0.06B 1.95
2010-03-31 $0.14B $0.08B 1.81
2009-12-31 $0.16B $0.08B 1.88
2009-09-30 $0.11B $0.09B 1.29
2009-06-30 $0.12B $0.08B 1.42
2009-03-31 $0.13B $0.08B 1.59
2008-12-31 $0.14B $0.08B 1.72
2008-09-30 $0.08B $0.07B 1.11
2008-06-30 $0.04B $0.03B 1.73
2008-03-31 $0.06B $0.03B 2.30
2007-12-31 $0.14B $0.03B 5.52
2007-09-30 $0.15B $0.02B 7.31
2007-06-30 $0.15B $0.02B 7.44
2007-03-31 $0.09B $0.02B 4.46
2006-12-31 $0.10B $0.02B 5.62
2006-09-30 $0.11B $0.02B 5.82
2006-06-30 $0.12B $0.02B 7.16
2006-03-31 $0.13B $0.02B 5.81
2005-12-31 $0.15B $0.04B 3.58
2005-09-30 $0.14B $0.02B 6.86
2005-06-30 $0.14B $0.02B 7.29
2005-03-31 $0.10B $0.02B 5.64
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.158B $0.026B
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $54.610B 34.89
Astellas Pharma (ALPMY) Japan $28.433B 13.94
Takeda Pharmaceutical (TAK) Japan $27.154B 7.97
UCB SA (UCBJF) Belgium $15.866B 0.00
Eisai (ESALY) Japan $15.807B 27.18
Grifols, S.A (GRFS) Spain $15.209B 19.24
Merck (MKGAF) Germany $13.448B 18.35
IPSEN SA ADR (IPSEY) France $10.783B 0.00
Ionis Pharmaceuticals (IONS) United States $9.649B 21.09
Sage Therapeutics (SAGE) United States $9.439B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Catalent (CTLT) United States $7.912B 31.75
Neurocrine Biosciences (NBIX) United States $7.824B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.738B 10.61
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 19.83
STADA ARZNEIMI (STDAF) Germany $5.634B 0.00
Nektar Therapeutics (NKTR) United States $5.573B 9.08
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.420B 0.00
Orion OYJ (ORINY) Finland $5.275B 27.16
Hypermarcas (HYPMY) Brazil $4.805B 16.89
Evotec AG (EVTCY) Germany $4.267B 45.80
Tilray (TLRY) Canada $4.238B 0.00
FibroGen (FGEN) United States $3.983B 0.00
United Therapeutics (UTHR) United States $3.300B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.220B 11.56
Arrowhead Pharmaceuticals (ARWR) United States $2.766B 416.71
PTC Therapeutics (PTCT) United States $2.514B 0.00
Xencor (XNCR) United States $2.513B 68.60
Zogenix (ZGNX) United States $2.035B 0.00
Portola Pharmaceuticals (PTLA) United States $1.814B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.658B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.647B 79.76
Enanta Pharmaceuticals (ENTA) United States $1.613B 22.04
CLINIGEN GP (CLIGF) United Kingdom $1.577B 0.00
USANA Health Sciences (USNA) United States $1.462B 12.71
Heron Therapeutics (HRTX) United States $1.461B 0.00
Corcept Therapeutics (CORT) United States $1.263B 18.03
Aerie Pharmaceuticals (AERI) United States $1.062B 0.00
Radius Health (RDUS) United States $1.035B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.986B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.879B 0.00
Endo (ENDP) Ireland $0.740B 1.19
Concordia (CXRXF) Canada $0.716B 0.00
Aptorum Group (APM) China $0.636B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.577B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.574B 0.00
Organogenesis Holdings (ORGO) United States $0.562B 0.00
TherapeuticsMD (TXMD) United States $0.543B 0.00
Karyopharm Therapeutics (KPTI) United States $0.505B 0.00
GlycoMimetics (GLYC) United States $0.482B 0.00
ChemoCentryx (CCXI) United States $0.474B 0.00
Translate Bio (TBIO) United States $0.472B 0.00
Akebia Therapeutics (AKBA) United States $0.457B 0.00
Dova Pharmaceuticals (DOVA) United States $0.452B 0.00
Dermira (DERM) United States $0.450B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.444B 22.38
Siga Technologies (SIGA) United States $0.440B 1.04
Catalyst Pharmaceuticals (CPRX) United States $0.417B 0.00
CV Sciences (CVSI) United States $0.413B 0.00
Flexion Therapeutics (FLXN) United States $0.412B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.403B 0.00
CannTrust Holdings (CTST) Canada $0.391B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.390B 0.00
Indivior (INVVY) United States $0.386B 1.39
BioCryst Pharmaceuticals (BCRX) United States $0.374B 0.00
Innate Pharma SA (IPHYF) France $0.364B 0.00
Harpoon Therapeutics (HARP) United States $0.348B 0.00
ImmunoGen (IMGN) United States $0.348B 0.00
Collegium Pharmaceutical (COLL) United States $0.346B 0.00
Xeris Pharmaceuticals (XERS) United States $0.331B 0.00
KalVista Pharmaceuticals (KALV) United States $0.305B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.288B 0.00
Molecular Templates (MTEM) United States $0.272B 0.00
Concert Pharmaceuticals (CNCE) United States $0.256B 0.00
OptiNose (OPTN) United States $0.250B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.236B 0.00
Lannett Co Inc (LCI) United States $0.235B 2.28
Recro Pharma (REPH) United States $0.220B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.215B 0.00
Ocular Therapeutix (OCUL) United States $0.195B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.193B 0.00
Redhill Biopharma (RDHL) Israel $0.178B 0.00
Nature's Sunshine Products (NATR) United States $0.175B 56.63
Taiwan Liposome (TLC) Taiwan $0.163B 0.00
Calithera Biosciences (CALA) United States $0.162B 0.00
Ardelyx (ARDX) United States $0.157B 0.00
IMV INC (IMV) Canada $0.152B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.151B 0.00
Jounce Therapeutics (JNCE) United States $0.136B 0.00
Majesco Entertainment (PTE) United States $0.132B 0.00
MEI Pharma (MEIP) United States $0.131B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.131B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.126B 0.00
DURECT (DRRX) United States $0.118B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Generex Biotechnology (GNBT) United States $0.107B 0.00
Aquestive Therapeutics (AQST) United States $0.103B 0.00
MediWound (MDWD) Israel $0.101B 0.00
RENEURON GP (RNUGF) United Kingdom $0.100B 0.00
Iterum Therapeutics (ITRM) Ireland $0.093B 0.00
Infinity Pharmaceuticals (INFI) United States $0.092B 0.00
Mast Therapeutics (SVRA) United States $0.089B 0.00
Champions Oncology (CSBR) United States $0.089B 768.00
Genocea Biosciences (GNCA) United States $0.089B 0.00
Capnia (SLNO) United States $0.088B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.088B 63.00
Nivalis Therapeutics (ALPN) United States $0.088B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.086B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.083B 0.00
Aclaris Therapeutics (ACRS) United States $0.082B 0.00
Cardiome Pharma (CORV) Canada $0.080B 0.00
Natural Alternatives (NAII) United States $0.079B 7.90
Otonomy (OTIC) United States $0.077B 0.00
China SXT Pharmaceuticals (SXTC) China $0.075B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.074B 0.00
Novan (NOVN) United States $0.070B 0.00
Neos Therapeutics (NEOS) United States $0.070B 0.00
Pharmaxis (PXSLY) Australia $0.067B 0.00
SCYNEXIS (SCYX) United States $0.066B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.055B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.055B 0.00
Medicure (MCUJF) Canada $0.053B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.051B 0.00